Successful pregnancy and delivery after ovulation induction therapy in a woman with congenital hypogonadotropic hypogonadism: a case report.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
11 May 2023
Historique:
received: 16 11 2022
accepted: 06 05 2023
medline: 15 5 2023
pubmed: 12 5 2023
entrez: 11 5 2023
Statut: epublish

Résumé

Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder resulting from a deficient secretion of the episodic gonadotropin-releasing hormone, leading to delayed or absent puberty and infertility. In female patients with CHH, the most commonly used treatment is gonadotropin (Gn) therapy. Due to the rarity of the disease in females, there are limited case reports available. This article offers a management approach for this unusual disease that can be helpful for clinicians. We report the case of a 29-year-old woman who successfully achieved pregnancy and delivered healthy twin girls after ovulation induction therapy. The patient was diagnosed with CHH at 18 years of age due to primary amenorrhea and the absence of secondary sexual characteristics. After experiencing infertility for three years, the patient sought medical assistance for conceiving. The patient was treated with gonadotropin therapy due to anovulation. In her first treatment cycle, the initial dose of HMG used for treatment was 75IU, which was increased to 150IU after six days. However, the cycle was canceled due to follicular dysplasia. In the second cycle, the treatment began with an initial dose of 150IU, and the follicles grew normally, but the estrogen level was low. Consequently, the treatment was interrupted. In a third ovulation stimulation cycle, HMG was adjusted to 150IU, and recombinant LH was added. After 12 days of ovulation, three mature follicles grew, the estrogen level was normal,and the treatment resulted in successful ovulation and subsequent pregnancy. At 35 weeks of gestation, the patient underwent a cesarean section and delivered two healthy female infants weighing 2,405 g and 2,755 g with an Apgar score of 10/10. Early diagnosis and timely and appropriate hormone replacement therapy are important for future pregnancy. Ovulation induction therapy is necessary to stimulate fertility. Gn therapy is a feasible and effective treatment for reproduction in CHH females, but the selection of Gn type and dosage must be personalized to maximize fertility outcomes. Effective treatment is available not only for inducing estrogenization and promoting fertility, but also for addressing concerns about psychological and emotional well-being.

Sections du résumé

BACKGROUND BACKGROUND
Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder resulting from a deficient secretion of the episodic gonadotropin-releasing hormone, leading to delayed or absent puberty and infertility. In female patients with CHH, the most commonly used treatment is gonadotropin (Gn) therapy. Due to the rarity of the disease in females, there are limited case reports available. This article offers a management approach for this unusual disease that can be helpful for clinicians.
CASE PRESENTATION METHODS
We report the case of a 29-year-old woman who successfully achieved pregnancy and delivered healthy twin girls after ovulation induction therapy. The patient was diagnosed with CHH at 18 years of age due to primary amenorrhea and the absence of secondary sexual characteristics. After experiencing infertility for three years, the patient sought medical assistance for conceiving. The patient was treated with gonadotropin therapy due to anovulation. In her first treatment cycle, the initial dose of HMG used for treatment was 75IU, which was increased to 150IU after six days. However, the cycle was canceled due to follicular dysplasia. In the second cycle, the treatment began with an initial dose of 150IU, and the follicles grew normally, but the estrogen level was low. Consequently, the treatment was interrupted. In a third ovulation stimulation cycle, HMG was adjusted to 150IU, and recombinant LH was added. After 12 days of ovulation, three mature follicles grew, the estrogen level was normal,and the treatment resulted in successful ovulation and subsequent pregnancy. At 35 weeks of gestation, the patient underwent a cesarean section and delivered two healthy female infants weighing 2,405 g and 2,755 g with an Apgar score of 10/10.
CONCLUSIONS CONCLUSIONS
Early diagnosis and timely and appropriate hormone replacement therapy are important for future pregnancy. Ovulation induction therapy is necessary to stimulate fertility. Gn therapy is a feasible and effective treatment for reproduction in CHH females, but the selection of Gn type and dosage must be personalized to maximize fertility outcomes. Effective treatment is available not only for inducing estrogenization and promoting fertility, but also for addressing concerns about psychological and emotional well-being.

Identifiants

pubmed: 37170100
doi: 10.1186/s12884-023-05682-7
pii: 10.1186/s12884-023-05682-7
pmc: PMC10173580
doi:

Substances chimiques

Gonadotropins 0
Gonadotropin-Releasing Hormone 33515-09-2
Estrogens 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

338

Subventions

Organisme : Beijing Municipal Administration of Hospitals Incubating Program
ID : PX2021054

Informations de copyright

© 2023. The Author(s).

Références

Eur J Endocrinol. 2010 May;162(5):835-51
pubmed: 20207726
Endocr Dev. 2016;29:72-86
pubmed: 26680573
Nat Rev Endocrinol. 2011 Oct 18;8(3):172-82
pubmed: 22009162
Ann Endocrinol (Paris). 2010 May;71(3):158-62
pubmed: 20363464
Ann Endocrinol (Paris). 2009 Mar;70(1):2-13
pubmed: 19200533
Nat Rev Endocrinol. 2015 Sep;11(9):547-64
pubmed: 26194704
Front Endocrinol (Lausanne). 2019 Jul 05;10:353
pubmed: 31333578
Endocr Rev. 2019 Apr 1;40(2):669-710
pubmed: 30698671
J Endocrinol Invest. 2012 Dec;35(11):996-1002
pubmed: 23095369
Clin Endocrinol (Oxf). 2008 Sep;69(3):471-8
pubmed: 18485121
J Clin Endocrinol Metab. 1998 May;83(5):1507-14
pubmed: 9589647
Biologics. 2009;3:337-47
pubmed: 19707419
Hum Reprod. 1995 Jul;10(7):1678-83
pubmed: 8582960
Eur J Endocrinol. 2021 May 04;184(6):R225-R242
pubmed: 33687345
Hum Fertil (Camb). 2021 Nov 9;:1-10
pubmed: 34753367
Endocr Rev. 2019 Oct 1;40(5):1285-1317
pubmed: 31220230
Curr Opin Obstet Gynecol. 1998 Jun;10(3):243-59
pubmed: 9619349
Clinics (Sao Paulo). 2013;68 Suppl 1:81-8
pubmed: 23503957
Ann Transl Med. 2021 Jun;9(12):962
pubmed: 34277762
Fac Rev. 2021 Apr 13;10:37
pubmed: 34046641
Endocr Connect. 2017 Aug;6(6):404-412
pubmed: 28698240
Endocr J. 2022 Jul 28;69(7):831-838
pubmed: 35236788
Gynecol Endocrinol. 2017 Aug;33(8):598-601
pubmed: 28277105

Auteurs

Yu Liang (Y)

Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100026, China.

Xiaokui Yang (X)

Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100026, China.

Ying Li (Y)

Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100026, China.

Lingling Lei (L)

Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100026, China.

Yonglian Lan (Y)

Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100026, China. yonglianlan@ccmu.edu.cn.

Shuyu Wang (S)

Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100026, China. wangshuyu@ccmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH